A Breakthrough HIV Drug. A Broken Supply Chain. Why Prevention Reaches the Wrong People First.

A new drug called lenacapavir is working. It's almost working too well.

In clinical trials across Uganda and other African countries, this twice-yearly injection prevented HIV transmission with stunning effectiveness. In PURPOSE 1, a trial of nearly 4,200 women, zero women acquired HIV after the drug became available. Adherence was above 96%. By any measure, this is a public health victory.

But here's the problem: the drug is rolling out unevenly. And it's rolling out in the wrong direction.

NPR's reporting from Uganda reveals what happens when a lifesaving medication meets a profit-driven supply chain. The countries that conducted the trials, where HIV prevalence is highest and resources are lowest, are getting the drug last. Wealthier nations with lower infection rates are getting it first. A young woman named Irene in central Uganda, who participated in the research that proved the drug works, now faces uncertainty about whether she'll have continued access once the trial ends.

Why This Matters

This isn't about whether lenacapavir works. It does. It's about who gets to benefit from medical breakthroughs.

Sub-Saharan Africa accounts for roughly 70% of all new HIV infections globally. Women make up the majority of new infections in that region. The PURPOSE 1 trial was designed to test the drug where it would save the most lives. And it did. The evidence proved it.

But evidence doesn't determine distribution. Money does.

Pharmaceutical companies sell to the highest bidder. Wealthy governments can negotiate bulk purchases and guarantee payment. Developing nations can't. So the drug that was tested in Uganda will be prescribed in Manhattan first. The woman who risked her reputation to participate in the trial has no guarantee she'll ever receive it.

The Pattern Nobody Talks About

This happens every time. Hepatitis C treatment. Cancer drugs. Vaccines. The pattern is always the same: breakthrough discovered in the Global South, rolled out first in the Global North, reaches the people who need it most last, if ever.

It's not malice. It's the system working exactly as designed. Pharmaceutical companies are accountable to shareholders, not to public health. Governments negotiate for their own citizens. The gaps in between? Nobody's responsible for those.

Irene asked NPR to use only her first name. She's afraid her community will assume she has HIV just for participating in an HIV trial. She'll give birth in three weeks. She did something brave for science. And the system that benefited from her courage is now prepared to leave her behind.